CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

idecabtagene vicleucel

Last Updated: November 19, 2020
Result type: Reports
Project Number: PG0240-000
Product Line: Reimbursement Review

Generic Name: idecabtagene vicleucel

Brand Name: TBC

Manufacturer: Celgene Inc., a Bristol Myers Squibb company

Therapeutic Area: Multiple myeloma

Indications: For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

Submission Type: Initial

Tumour Type: Myeloma

Project Status: Pending

Call for patient/clinician input open: November 19, 2020

Call for patient/clinician input closed: January 15, 2021

Anticipated Date: December 16, 2020

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback